Table 3.
| Associated disease |
Patients with type 1 diabetes |
General population |
||
| Prevalence of organ-specific Abs | Overt disease | Prevalence of organ-specific Abs | Overt disease | |
| Type 1 diabetes | ICA in 85%-90% | 100% | ICA in 1%-3 % | 0.1%-1.0% |
| Hashimoto’s thyroiditis | TPO Abs in 15%-30% | 10%-20% | TPO Abs in 2%-10% | 0.5%-9.0% |
| Graves’ disease | TSH-R Abs in 1%-18% | 3%-6% | TSH-R Abs in 1%-2% | 0.1%-2.0% |
| Addison’s disease | 21-OH Abs in 0.7%-2.0% | 0.5%-0.8% | 21-OH Abs in 0.6% | 0.005%-0.140% |
| Autoimmune hypophysitis and/or hypopituitarism | Pituitary Abs in 3.6% | 0.4%-0.9% | Pituitary Abs in 0.5% | 0.24%-0.80% |
| Autoimmune type A gastritis and pernicious anemia | Gastric parietal cell Abs in 13%-25% | 5%-10% (2%-6%) | Gastric parietal cell Abs in 2.5%-12.0% | 2% (0.15%-1.00%) |
| Celiac disease | Transglutaminase Abs in 8%-12% | 1%-9% | Transglutaminase Abs in 0.5%-1.0% | 0.50% |
Abs: Antibodies; ICA: Islet cell antibodies; TPO: Thyroperoxidase; TSH-R: Thyrotropin receptor antibodies; 21-OH: 21 Hydroxylase.